参考文献/References:
[1]Larkin?J,Chiarion-Sileni?V,Gonzalez?R,et?al.?Five-Year?survival?with?combined?nivolumab?and?ipilimumab?in?advanced?melanoma[J].?N?Engl?J?Med?2019,381(16):1535-1546.
[2]Drobni ZD,Alvi RM,Taron J,et al. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque[J]. Circulation,2020,142(24):2299-2311.
[3]Sun Z,Fourcade J,Pagliano O,et al. IL10 and PD-1 cooperate to limit the activity of tumor-specific CD8+ T cells[J].?Cancer Res,2015,75(8):1635-1644.
[4]Chow A,Perica K,Klebanoff CA,et al. Clinical implications of T cell exhaustion for cancer immunotherapy[J].?Nat Rev Clin Oncol,2022,19(12):775-790.?
[5]Sun C,Mezzadra R,Schumacher TN. Regulation and function of the PD-L1 checkpoint[J]. Immunity,2018,48(3):434-452.?
[6]Leitinger N,Schulman IG. Phenotypic polarization of macrophages in atherosclerosis[J]. Arterioscler Thromb Vasc Biol,2013,33(6):1120-1126.
[7]Barrett TJ. Macrophages in atherosclerosis regression[J]. Arterioscler Thromb Vasc Biol,2020,40(1):20-33.
[8]Wang,Z,Zhang,X,Lu,S,et al.?Pairing of single-cell RNA analysis and T cell antigen receptor profiling indicates breakdown of T cell tolerance checkpoints in atherosclerosis[J].?Nat Cardiovasc Res,2023,2(3):290-306.?
[9]Koltsova EK,Garcia Z,Chodaczek G,et al. Dynamic T cell—APC interactions sustain chronic inflammation in atherosclerosis[J]. J Clin Invest,2012,122(9):3114-3126.
[10]Lee LY,Oldham WM,He H,et al. Interferon-γ impairs human coronary artery endothelial glucose metabolism by tryptophan catabolism and activates fatty acid oxidation[J]. Circulation,2021,144(20):1612-1628.
[11]im CW,Oh ET,Park HJ. A strategy to prevent atherosclerosis via TNF receptor regulation[J]. FASEB J,2021,35(3):e21391.
[12]Wang Q,Wang Y,Xu D. Research progress on Th17 and T regulatory cells and their cytokines in regulating atherosclerosis[J].?Front Cardiovasc Med,2022,9:929078.?
[13]Foks AC,Lichtman AH,Kuiper J. Treating atherosclerosis with regulatory T cells[J]. Arterioscler Thromb Vasc Biol,2015,35(2):280-287.
[14]Kimura T,Kobiyama K,Winkels H,et al. Regulatory CD4+ T cells recognize major histocompatibility complex class Ⅱ molecule-restricted peptide epitopes of apolipoprotein B[J]. Circulation,2018,138(11):1130-1143.
[15]Saigusa R,Winkels H,Ley K. T cell subsets and functions in atherosclerosis[J]. Nat Rev Cardiol,2020,17(7):387-401.
[16]Vallejo J,Cochain C,Zernecke A,et al. Heterogeneity of immune cells in human atherosclerosis revealed by scRNA-Seq[J].?Cardiovasc Res,2021,117(13):2537-2543.
[17]Cochain C,Vafadarnejad E,Arampatzi P,et al. Single-cell RNA-Seq reveals the transcriptional landscape and heterogeneity of aortic macrophages in murine atherosclerosis[J]. Circ Res,2018,122(12):1661-1674.
[18]Kolbus D,Ramos OH,Berg KE,et al. CD8+ T cell activation predominate early immune responses to hypercholesterolemia in Apoe?/? mice[J].?BMC Immunol,2010,11:58.?
[19]Matsumoto T,Sasaki N,Yamashita T,et al. Overexpression of cytotoxic T-lymphocyte-associated antigen-4 prevents atherosclerosis in mice[J]. Arterioscler Thromb Vasc Biol,2016,36(6):1141-1151.?
[20]Poels K,van Leent MMT,Boutros C,et al. Immune checkpoint inhibitor therapy aggravates T cell-driven plaque inflammation in atherosclerosis[J]. JACC CardioOncol,2020,2(4):599-610.
[21]Hu YB,Zhang Q,Li HJ,et al. Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer:a meta-analysis[J]. Transl Lung Cancer Res,2017,6(suppl 1):S8-S20.
[22]Buono C,Pang H,Uchida Y,et al. B7-1/B7-2 costimulation regulates plaque antigen-specific T-cell responses and atherogenesis in low-density lipoprotein receptor-deficient mice[J]. Circulation,2004,109(16):2009-2015.
[23]Zhao B,Wang D,Liu Y,et al. Six-gene signature associated with immune cells in the progression of atherosclerosis discovered by comprehensive bioinformatics analyses[J]. Cardiovasc Ther,2020,2020:1230513.
[24]Ewing MM,Karper JC,Abdul S,et al. T-cell co-stimulation by CD28-CD80/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development[J]. Int J Cardiol,2013,168(3):1965-1974.
[25]Johnson DB,Nebhan CA,Moslehi JJ,et al. Immune-checkpoint inhibitors:long-term implications of toxicity[J]. Nat Rev Clin Oncol,2022,19(4):254-267.
[26]Veluswamy P,Wacker M,Scherner M,et al. Delicate role of PD-L1/PD-1 axis in blood vessel inflammatory diseases:current insight and future significance[J]. Int J Mol Sci,2020,21(21):8159.
[27]Ali AJ,Makings J,Ley K. Regulatory T cell stability and plasticity in atherosclerosis[J]. Cells,2020,9(12):2665.
[28]Grievink HW,Smit V,Verwilligen RAF,et al. Stimulation of the PD-1 pathway decreases atherosclerotic lesion development in Ldlr deficient mice[J]. Front Cardiovasc Med,2021,8:740531.
[29]Li SH,Chen WJ,Yan M,et al. Expression of coinhibitory PD-L1 on CD4?CD25?FOXP3? regulatory T cells is elevated in patients with acute coronary syndrome[J]. Coron Artery Dis,2015,26(7):598-603.
[30]Zhou J,Lee S,Lakhani I,et al. Adverse Cardiovascular Complications following prescription of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors: a propensity-score matched cohort study with competing risk analysis[J].?Cardiooncology,2022,8(1):5.
[31]Richards DM,Sefrin JP,Gieffers C,et al. Concepts for agonistic targeting of CD40 in immuno-oncology[J]. Hum Vaccines Immunother,2020,16(2):377-387.
[32]Yuan M,Fu H,Ren L,et al. Soluble CD40 ligand promotes macrophage foam cell formation in the etiology of atherosclerosis[J]. Cardiology,2015,131(1):1-12.
[33]Lutgens E,Lievens D,Beckers L,et al. Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile[J]. J Exp Med,2010,207(2):391-404.
[34]Lacy M,Bürger C,Shami A,et al. Cell-specific and divergent roles of the CD40L-CD40 axis in atherosclerotic vascular disease[J]. Nat Commun,2021,12(1):3754.
[35]Shevach EM,Stephens GL. The GITR-GITRL interaction:co-stimulation or contrasuppression of regulatory activity?[J]. Nat Rev Immunol,2006,6(8):613-618.
[36]Zappasodi R,Sirard C,Li Y,et al. Rational design of anti-GITR-based combination immunotherapy[J]. Nat Med,2019,25(5):759-766.
[37]Shami?A,Atzler?D,Bosmans?LA,et?al.?Glucocorticoid-induced tumour necrosis factor receptor family-related protein (GITR) drives atherosclerosis in mice and is associated with an unstable plaque phenotype and cerebrovascular events in humans[J].?Eur Heart J,2020,41(31):2938-2948.?
[38]Bar J,Markel G,Gottfried T,et al. Acute vascular events as a possibly related adverse event of immunotherapy:a single-institute retrospective study[J]. Eur J Cancer,2019,120:122-131.
[39]Ridker PM,Bhatt DL,Pradhan AD,et al. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy:a collaborative analysis of three randomised trials[J]. Lancet,2023,401(10384):1293-1301.
[40]Tardif JC,Kouz S,Waters DD,et al. Efficacy and safety of low-dose colchicine after myocardial infarction[J]. N Engl J Med,2019,381(26):2497-2505.
相似文献/References:
[1]史云聪 郭艺芳.2型糖尿病和动脉粥样硬化性心血管疾病的关系[J].心血管病学进展,2020,(5):485.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.011]
SHI Yuncong,GUO Yifang.Relationship Between Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(2):485.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.011]
[2]李艳茹,白世茹,李如意,等.PCSK9抑制剂在血脂代谢中的研究进展[J].心血管病学进展,2020,(7):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
LI Yanru,BAI Shiru,LI Ruyi,et al.PCSK9 Inhibitors in Lipid Metabolism[J].Advances in Cardiovascular Diseases,2020,(2):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
[3]马晓磊 朱国斌.Wnt信号与动脉粥样硬化性心血管疾病研究进展[J].心血管病学进展,2020,(8):855.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.018]
MA Xiaolei,ZHU Guobin.Wnt Signaling and Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(2):855.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.018]
[4]黄毕.慢性肾脏病合并动脉粥样硬化性心血管疾病的调脂治疗进展[J].心血管病学进展,2020,(10):1065.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.016]
HUANG Bi.Lipid Management in Patients with Chronic Kidney Disease and Arteriosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(2):1065.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.016]
[5]姚雅洁 蔡恒.PCSK9抑制剂Evolocumab动脉粥样硬化性心血管疾病的研究进展[J].心血管病学进展,2020,(12):1285.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.015]
YAO Yajie,CAI Heng.PCSK9 Inhibitor Evolocumab and ASCVD[J].Advances in Cardiovascular Diseases,2020,(2):1285.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.015]
[6]曹岩 颜培实.残余胆固醇与动脉粥样硬化性心血管疾病[J].心血管病学进展,2021,(10):920.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.014]
CAO Yan,YAN Peishi.Remnant Cholesterol And Atherosclerotic?ardiovascular Disease[J].Advances in Cardiovascular Diseases,2021,(2):920.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.014]
[7]蔡薇 杨堰焯 刘昊凌.甘油三酯葡萄糖乘积指数与糖尿病血管病变的研究进展[J].心血管病学进展,2022,(3):245.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
CAI Wei,YANG Yanzhuo,LIU Haoling.Triglyceride-Glucose Index and Diabetic Vascular Disease[J].Advances in Cardiovascular Diseases,2022,(2):245.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
[8]陈林滔 田清平 刘梅林.残余胆固醇预测动脉粥样硬化性心血管疾病的研究进展[J].心血管病学进展,2022,(6):492.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.004]
CHEN Lintao,TIAN Qingping,LIU Meilin.Remnant Cholesterol in Predicting Atherosclerotic Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2022,(2):492.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.004]
[9]肖乾凤 王斯 刘燕扬 魏欣.免疫检查点抑制剂相关性心肌炎的诊治[J].心血管病学进展,2022,(7):610.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
Inhibitors-Related Myocarditis.Diagnosis and Treatment of Immune Checkpoint[J].Advances in Cardiovascular Diseases,2022,(2):610.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
[10].胆固醇酯转移蛋白抑制剂在动脉粥样硬化性心血管疾病治疗中的研究进展[J].心血管病学进展,2022,(7):600.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
ZHU Jie,GAO Fen,XUE Shuanqin,et al.Treatment of Atherosclerotic Cardiovascular Diseases with Cholesteryl Ester Transfer Protein Inhibitor[J].Advances in Cardiovascular Diseases,2022,(2):600.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]